Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0R7ID
|
|||
Former ID |
DCL000128
|
|||
Drug Name |
HMN-214
|
|||
Synonyms |
N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Pancreatic cancer [ICD-11: 2C10] | Discontinued in Phase 1 | [1] | |
Prostate cancer [ICD-11: 2C82.0] | Discontinued in Phase 1 | [1] | ||
Therapeutic Class |
Anticancer Agents
|
|||
Company |
Nippon Shinyaku
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H20N2O5S
|
|||
Canonical SMILES |
CC(=O)N(C1=CC=CC=C1C=CC2=CC=[N+](C=C2)[O-])S(=O)(=O)C3=CC=C(C=C3)OC
|
|||
InChI |
1S/C22H20N2O5S/c1-17(25)24(30(27,28)21-11-9-20(29-2)10-12-21)22-6-4-3-5-19(22)8-7-18-13-15-23(26)16-14-18/h3-16H,1-2H3/b8-7+
|
|||
InChIKey |
OCKHRKSTDPOHEN-BQYQJAHWSA-N
|
|||
CAS Number |
CAS 173529-46-9
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
14856179, 24174667, 45635528, 80239942, 126671560, 131301966, 134338811, 135261881, 136340321, 136367924, 144116052, 162011382, 162037628, 162202558, 163688748, 177748947, 185998805, 188932423, 198973004, 223661711, 223705120, 225057944, 231030713, 231030719, 251962911, 251971341, 252110131, 252215548, 252450708
|
|||
ChEBI ID |
CHEBI:91440
|
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010558) | |||
REF 2 | Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. | |||
REF 3 | A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res. 2006 Sep 1;12(17):5182-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.